PRF Technologies Ltd
prf-tech.comWhat Do They Do?
Develops AI-driven solar analytics solutions for solar energy companies, solar field maintenance providers, and homeowners.
20-F for FY2025, filed Mar 26, 2026
How Do They Make Money?
-
20-F for FY2025, filed Mar 26, 2026
FY2025 revenue by reportable segment ↗
$17K
-
20-F for FY2025, filed Mar 26, 2026
$17K ↗
| Segment | Share | Revenue |
|---|---|---|
|
Solar By Business Segments
|
100% |
Solar By Business Segments, FY2025
$17K Sources
|
|
Clinical Development By Business Segments
|
0.0% |
Clinical Development By Business Segments, FY2025
$0 Sources
|
Who Are Their Customers?
The company has limited sales and marketing infrastructure and may build its own sales organization or out-license sales and marketing.
20-F for FY2025, filed Mar 26, 2026We have a very limited sales and marketing infrastructure and are in the very early stages of commercializing the DeepSolar solution having…View ↗
Do Revenues Turn Into Profits?
No. It lost $5M in FY2025.
20-F for FY2025, filed Mar 26, 2026
−$5.1MView ↗
20-F for FY2025, filed Mar 26, 2026
−$5MView ↗
20-F for FY2025, filed Mar 26, 2026
−$4MView ↗
How Are They Changing?
Solar analytics
The older report describes a clinical-stage pharmaceutical developer; the latest also includes AI-driven solar analytics after acquiring DeepSolar's business operations.
20-F for FY2022, filed Mar 15, 2023 20-F for FY2025, filed Mar 26, 2026We are a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Our proprietary…View ↗
We are a specialty pharmaceutical company focused on the reformulation of established therapeutics. Our proprietary extended-release…View ↗
Drug development focus
The older report centers on a post-surgical pain drug candidate and planned further trials; the latest says development of that candidate was scaled back after the trial missed its main goal, and adds a sustained-release eye treatment.
20-F for FY2022, filed Mar 15, 2023 20-F for FY2025, filed Mar 26, 2026
Who Do They Compete With?
Competes with Pacira Pharmaceuticals, Heron Therapeutics, Hospira, Fresenius Kabi USA, Optomed, PanOptica, Lenz Therapeutics, and Rayner
20-F for FY2025, filed Mar 26, 2026If we are able to successfully develop PRF-110 for postoperative pain management, we will compete with Exparel® (bupivacaine liposome…View ↗
Loading...
